About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
DCB coating designs and particulate levels
By
Philips
By
Philips
127 views
April 7, 2021
Explore how paclitaxel form and excipient coatings may affect particulate loss
0 Comments
Login to view comments.
Click here to Login
Related Content
AUTOPLAY
ON
01:09
Philips
DCB coating reactions vary when hydrated
01:52
Philips
Paclitaxel Mechanism of Action
61:28
Philips
Post-PTA dissection repair webinar at VIVA 2020
Feat.
J. Rundback,
E. Armstrong,
W. Gray,
P. Geraghty
02:23
Philips
Drug-coated balloon excipients role in coating durability
01:19
Philips
Explore Paclitaxel forms: amorphous vs crystalline
13:10
TCT 2023 Insights
TCT 2023 Insights: Best CLTI Case of The Year
Feat.
H. Lichaa
10:25
NY Endovascular Summit
Drug-Eluting Technology for Below-the-Knee Intervention
Feat.
M. Bunte
09:46
NY Endovascular Summit
The Sirolimus Option
Feat.
A. Virmani Finn
66:39
Philips
Live Case with Dr. George Adams and Philips Laser Atherectomy
Feat.
G. Adams
08:30
Philips
Stellarex DCB Design and Performance for Proven Clinical Success
17:24
ARCH Advanced Revascularization Symposium
Interventional Tool Kit (Guide Wires / Balloons, etc.)
Feat.
G. Chrysant
01:09
Philips
DCB coating reactions vary when hydrated
01:19
Philips
Explore Paclitaxel forms: amorphous vs crystalline
09:56
CVC 2018
DES for Infra-Popliteal Disease: What’s the Latest Data?
Feat.
P. Soukas
32:49
NY Endovascular Summit
Superficial Femoral Artery In-Stent Restenosis Intervention
Feat.
G. Adams,
A. Carroccio,
S. Tummala,
N. Shammas,
C. Bianchi,
S. Jenkins
01:52
Philips
Paclitaxel Mechanism of Action
02:23
Philips
Drug-coated balloon excipients role in coating durability
10:33
NY Endovascular Summit
Femoropopliteal Artery Disease and Treatment Options / Literature Re…
Feat.
S. Parikh
07:57
Complex Coronary Valvular and Vascular Cases Conference
Latest Techniques and Outcomes for Management of Chronic Venous Occl…
Feat.
R. Patel
11:25
ARCH Advanced Revascularization Symposium
Treatment of Femoral-Popliteal Disease: What Are the Factors that Ne…
Feat.
A. Thomas
06:16
NY Endovascular Summit
Q&A: Therapy in Severely Calcific SFA CTO: DES, DCB, and BMS
Feat.
B. DeRubertis,
C. Bianchi,
S. Tummala,
S. Jenkins
16:33
ARCH Advanced Revascularization Symposium
Top Vascular Trials of the Past Three Years
Feat.
S. Parikh
09:50
Complex Interventional Cardiovascular Therapy (CICT) 2018
Re-Stenting is the Only Proven Effective Treatment
Feat.
C. Grines
19:47
New Cardiovascular Horizons (NCVH) 2016
Antegrade Right Femoral Access and Drug Coated Balloon Angioplasty f…
Feat.
T. Zeller
12:02
Mount Sinai Endovascular Fellows Course
In-Stent Restenosis Treatment Options: Are DCB and Covered Stents Be…
Feat.
J. Titano